Clinical Trial

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Study acronym: LIBRA
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or metastatic NSCLC. The study will consist of several sub-studies, each evaluating the safety, tolerability, and preliminary antitumour activity of various treatment combinations. This study will be conducted in approximately 80 centers globally across 10 countries.
Protocol Amendment History 1 change
notable Trial sites expanded: 64 -> 83 locations 2026-05-28
Trial Details
NCT Number NCT07098338
Lead Sponsor AstraZeneca
Collaborators: Daiichi Sankyo
Conditions Non-Small Cell Lung Cancer
Enrollment 278 participants
Start Date 2025-08-07
Primary Completion 2029-04-06 (estimated)
Study Completion 2029-04-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-01